Literature DB >> 28848206

Number of Oocytes Retrieved as a Criterion for "Freeze-All" Strategy versus a Single "Rescue" Bolus of Low-Dose Human Chorionic Gonadotropin Following GnRH Agonist for Ovulation Triggering: A Pilot Study.

Roni Rahav Koren1, Ofer Gonen, Anat Hershko Klement, Einat Haikin Herzberger, Yehudith Ghetler, Adrian Shulman, Amir Wiser.   

Abstract

AIM: To evaluate the number of oocytes retrieved as a criterion - when to use a "freeze-all" or low-dose "rescue human chorionic gonadotropin (hCG)" strategy.
METHODS: A retrospective study. Instead of the classic hCG trigger, an E2 level of ≥3,000 pg/mL was used to trigger ovulation with GnRH agonist. The decision whether to "freeze all" or perform fresh embryo transfer (ET) with a bolus of hCG was made based on a maximum number of 20 oocytes retrieved. Beyond this cut off, a "freeze-all" strategy was implemented. Below this cut-off value, a fresh ET using a single bolus of 62.5 µg hCG on day 3 following oocyte pick-up was performed. The main outcome measures were clinical pregnancy rates and ovarian hyperstimulation syndrome (OHSS).
RESULTS: E2 and progesterone levels increased after the rescue hCG bolus administration (E2 from 643.4 ± 311.1 to 1,086.1 ± 574.7 pg/mL, p = 0.003 and progesterone from 13.1 ± 4.8 to 39.2 ± 28.7 ng/mL, p < 0.0001). The clinical pregnancy rates were 25% in the freeze-all group and 32% in the rescue hCG group (p = 0.57). OHSS was not reported in either group.
CONCLUSIONS: Both strategies seem to be efficacious and safe. An upper limit of 20 retrieved oocytes appears to be safe for applying a rescue hCG strategy.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Cycle segmentation; GnRH agonist; Low-dose human chorionic gonadotropin; Luteal phase support

Mesh:

Substances:

Year:  2017        PMID: 28848206     DOI: 10.1159/000479557

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  1 in total

1.  GnRH agonist-triggering ovulation in women with advanced age.

Authors:  Einat Haikin Herzberger; Amir Wiser; Roni Rahav Koren; Netanella Miller; Rimon Moran; Dean Decter; Arie Berkowitz
Journal:  Sci Rep       Date:  2022-09-30       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.